Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Effector Therapeutics Inc (NQ: EFTR )

1.940 -0.040 (-2.02%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 61,554
Open 1.980
Bid (Size) 1.940 (4)
Ask (Size) 2.150 (2)
Prev. Close 1.980
Today's Range 1.920 - 2.000
52wk Range 0.3550 - 17.75
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
EFTR Stock Earnings: eFFECTOR Therapeutics Meets EPS for Q1 2024
EFTR stock results show that eFFECTOR Therapeutics met analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga

Performance

YTD
+295.92%
+295.92%
1 Month
-2.51%
-2.51%
3 Month
-83.36%
-83.36%
6 Month
+223.33%
+223.33%
1 Year
+107.49%
+107.49%

More News

Read More
eFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
From eFFECTOR Therapeutics, Inc.
Via GlobeNewswire
eFFECTOR Therapeutics to Participate in Upcoming Investor Conference
From eFFECTOR Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Dow Dips Over 200 Points; RPM International Shares Fall After Q3 Results
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Nasdaq Surges 1%; ConAgra Brands Posts Upbeat Earnings
Via Benzinga
Topics Stocks
Exposures US Equities
Why STAAR Surgical Shares Are Trading Higher By Around 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Cancer-Focused eFFECTOR Therapeutics Shelves Development Of Lung Cancer Candidate After Disappointing Data
Via Benzinga
Dow Jumps Over 100 Points; US Jobless Claims Increase To 221,000
Via Benzinga
Topics Stocks
Exposures US Equities
eFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer
From eFFECTOR Therapeutics, Inc.
Via GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
EFTR Stock Earnings: eFFECTOR Therapeutics Misses EPS for Q4 2023
Via InvestorPlace
eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
From eFFECTOR Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
eFFECTOR Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
From eFFECTOR Therapeutics, Inc.
Via GlobeNewswire
eFFECTOR Therapeutics Announces Closing of $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
From eFFECTOR Therapeutics, Inc.
Via GlobeNewswire
eFFECTOR Therapeutics Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
From eFFECTOR Therapeutics, Inc.
Via GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Dow Tumbles Over 200 Points; US Trade Gap Narrows In November
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
eFFECTOR Therapeutics to Host Virtual Investor R&D Day on January 24, 2024
From eFFECTOR Therapeutics, Inc.
Via GlobeNewswire
eFFECTOR Therapeutics Announces Reverse Stock Split
From eFFECTOR Therapeutics, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.